Article Text

Download PDFPDF
Loss of phosphatase and tensin homologue deleted on chromosome 10 and phosphorylation of mammalian target of rapamycin are associated with progesterone refractory endometrial hyperplasia
  1. M. R. Milam*,
  2. P. T. Soliman*,
  3. L. H. Chung*,
  4. K. M. Schmeler*,
  5. JR R. L. Bassett,
  6. R. R. Broaddus and
  7. K. H. Lu*
  1. *Department of Gynecologic Oncology,
  2. Division of Quantitative Sciences, and
  3. Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas
  1. Address correspondence and reprint requests to: Karen H. Lu, MD, Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, 1155 Herman P. Pressler Street, CPB 6.3244, Unit 1362, Houston, TX 77030, USA. Email: khlu{at}


The objective of our study was to evaluate the phosphatase and tensin homologue deleted on chromosome 10 (PTEN), p27, and mammalian target of rapamycin (mTOR) expressions in women with progesterone-responsive and refractory endometrial hyperplasia (EH) samples and to determine if these markers could be associated with response or used as potential targets for treatment. Thirty-eight matched pre- and posttreatment pairs of paraffin-embedded endometrial biopsies were obtained from patients with EH. Immunohistochemical analysis for PTEN, p27, and phospho-mTOR were performed on all samples. Median age at diagnosis was 49 years (20–79 years). Median treatment interval was 3 months (1–12 months). Sixteen patients (42.1%) had complete resolution of their hyperplasia (responders), and 22 (57.9%) had persistent hyperplasia (nonresponders) after treatment with progesterone. In the pretreatment samples, no markers were found to predict nonresponders. In posttreatment samples, loss of PTEN expression with phospho-mTOR expression was observed in more nonresponders than responders (40.9% vs 6.3%; P= 0.03). Phospho-mTOR overexpression was found in 63.6% of nonresponders. We found that persistent hyperplasia refractory to progesterone therapy was associated both with the loss of PTEN and with the loss of phosphorylation of mTOR. In select cases of non–responsive progesterone refractory EH, a rational target for treatment may involve the mTOR pathway.

  • endometrial hyperplasia
  • mTOR
  • progesterone
  • PTEN

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • This work was presented at the 42nd Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida, May 13–17, 2005.